GlassScriptPhysician profile
Anna Cauthen Mcfather
NPI 1124501184
$13,130.93
in general payments reported to CMS, 2019-2025
70 companies · $1,395 in 2025
The $1,395 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,257 · 2022: $2,856 · 2023: $2,884 · 2024: $3,739 · 2025: $1,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,119 · Long Term Medical Supply Or Device Loan: $899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,119.37 |
| Long Term Medical Supply Or Device Loan | $898.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,790.94 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $799.62 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $778.86 | 2021-2025 | Darzalex, Talvey, Erleada |
| Daiichi Sankyo INC. | $646.75 | 2021-2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $515.62 | 2021-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Eisai INC. | $466.74 | 2021-2025 | |
| Seagen INC. | $445.96 | 2021-2023 | Adcetris, Padcev, Tukysa |
| Glaxosmithkline, LLC. | $434.73 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Pharmacyclics LLC, An Abbvie Company | $416.19 | 2021-2023 | Imbruvica, Epkinly |
| Genzyme Corporation | $387.28 | 2021-2025 | |
| Celgene Corporation | $352.67 | 2021-2024 | Reblozyl, Opdualag |
| Amgen INC. | $329.47 | 2021-2023 | Lumakras, Nplate, Xgeva |
| Pfizer INC. | $313.93 | 2021-2024 | |
| Exelixis INC. | $291.93 | 2021-2024 | Cabometyx |
| Incyte Corporation | $277.41 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $273.60 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $267.31 | 2021-2024 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $266.55 | 2021-2025 | Tagrisso, Lynparza, Calquence |
| Gilead Sciences, INC. | $252.08 | 2021-2024 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $233.26 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $228.43 | 2021-2025 | |
| Karyopharm Therapeutics INC. | $218.23 | 2021-2024 | Xpovio |
| Genentech USA, INC. | $212.94 | 2021-2025 | Alecensa, Venclexta, Lunsumio |
| Sobi, INC | $178.09 | 2022-2024 | |
| Beigene USA, INC. | $167.44 | 2021-2025 | Brukinsa, Tevimbra |
| Adaptive Biotechnologies Corporation | $165.68 | 2022-2025 | Clonoseq |
| Puma Biotechnology, INC. | $149.51 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $147.64 | 2022-2025 | Ultomiris |
| Epizyme, INC. | $146.59 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $127.54 | 2021-2024 | Onivyde |
| Astellas Pharma US INC | $119.05 | 2021-2025 | Padcev, Xtandi |
| Kite Pharma, INC. | $107.88 | 2021-2023 | Yescarta |
| Adc Therapeutics America, INC. | $107.61 | 2022-2025 | |
| Tersera Therapeutics LLC | $105.64 | 2021-2025 | Xermelo, Zoladex |
| Deciphera Pharmaceuticals INC. | $95.90 | 2021-2023 | Qinlock |
| Rigel Pharmaceuticals, INC. | $89.02 | 2022-2023 | Tavalisse, Rezlidhia |
| Lilly USA, LLC | $81.49 | 2021-2023 | Verzenio, Jaypirca |
| Emd Serono, INC. | $79.01 | 2021-2025 | Tepmetko |
| Aveo Pharmaceuticals, INC. | $71.01 | 2022-2024 | Fotivda |
| Sumitomo Pharma America, INC. | $64.27 | 2023-2025 | Orgovyx |
| G1 Therapeutics, INC. | $59.50 | 2022-2023 | Cosela |
| Stemline Therapeutics INC. | $57.14 | 2023-2024 | Orserdu |
| Blueprint Medicines Corporation | $56.84 | 2022-2025 | Ayvakit |
| Servier Pharmaceuticals LLC | $54.73 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $51.08 | 2021-2023 | |
| Coherus Oncology, INC. | $49.24 | 2022 | |
| Pharmaessentia USA Corporation | $44.84 | 2025 | Besremi |
| Apellis Pharmaceuticals, INC. | $39.19 | 2022-2025 | Empaveli |
| Array Biopharma INC | $39.13 | 2021-2022 | |
| Genmab U.S., INC. | $37.04 | 2024 | Epkinly |
| Janssen Pharmaceuticals, INC | $33.72 | 2025 | Erleada |
| Mirati Therapeutics, INC. | $31.78 | 2024 | Krazati |
| Heron Therapeutics, INC. | $30.83 | 2022 | |
| Acrotech Biopharma INC. | $28.91 | 2022-2024 | Beleodaq |
| Delcath Systems | $26.47 | 2025 | Hepzato Kit |
| Eusa Pharma (US) LLC | $25.96 | 2021 | |
| Taiho Oncology, INC. | $24.02 | 2023 | |
| Cti Biopharma Corp. | $23.62 | 2022 | |
| Legend Biotech USA INC. | $22.27 | 2025 | Carvykti |
| Novocure INC. | $22.14 | 2021 | |
| Pharmacosmos Therapeutics INC. | $20.69 | 2024 | Cosela |
| Recordati_rare_diseases_inc. | $19.88 | 2024 | Sylvant |
| Geron Corporation | $19.42 | 2024 | Rytelo |
| Kyowa Kirin, INC. | $19.37 | 2023 | Poteligeo |
| Myovant Sciences INC. | $17.50 | 2022 | |
| Spectrum Pharmaceuticals INC. | $16.66 | 2024 | Rolvedon |
| Accord Healthcare, INC. | $15.20 | 2025 | |
| Foundation Medicine, INC. | $14.46 | 2022 | |
| Dova Pharmaceuticals | $14.13 | 2021 | |
| Amag Pharmaceuticals, INC. | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Mcfather listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.